Pars plana vitrectomy for disturbing primary vitreous floaters: clinical outcome and patient satisfaction
- PMID: 23250478
- DOI: 10.1007/s00417-012-2205-3
Pars plana vitrectomy for disturbing primary vitreous floaters: clinical outcome and patient satisfaction
Abstract
Background: Primary vitreous floaters can be highly bothersome in some patients. In the case of persistently bothersome floaters, pars plana vitrectomy may be the most effective treatment. The aim of this study is to evaluate the incidence of complications, and patient satisfaction, after pars plana vitrectomy for disabling primary vitreous opacities.
Methods: We included a total of 110 eyes that underwent pars plana vitrectomy between February 1998 and August 2010. Fifty-seven eyes (51.8%) underwent 20-gauge vitrectomy, whereas 53 eyes (48.2%) underwent 23-gauge vitrectomy. In a retrospective manner, we assessed intraoperative and postoperative complications. There was a considerable range of time between surgery and questionnaire (range: 4-136 months). Patient satisfaction was assessed by a questionnaire based on a modified NEI VFQ-25 questionnaire.
Results: A retinal detachment occurred in 10.9% of cases, and the incidence did not differ significantly between the 20-gauge and 23-gauge vitrectomy groups. In 4.5% of the eyes, a retinal detachment developed within the first 3 months, and 6.4% occurred later in the postoperative period. Cystoid macular edema occurred in 5.5%, and an epiretinal membrane was seen postoperatively in 3.6% of cases. Development of glaucoma requiring glaucoma surgery, a macular hole, and postoperative scotoma, each occurred in 0.9% of cases. No cases of endophthalmitis occurred. Eighty-five percent of patients were satisfied or very satisfied with the results of the vitrectomy. Eighty-four percent of all patients were completely cured from their troublesome vitreous floaters, and an additional 9.3% of patients were less troubled by vitreous floaters. Ten patients (9.3%) were dissatisfied, and six of these patients (5.6%) had a serious complication that resulted in permanent visual loss.
Conclusions: Pars plana vitrectomy is an effective approach to treat primary vitreous floaters, resulting in a high rate of patient satisfaction. Postoperative complications may be more frequent than previously reported, so patients should be well-informed about the complication rate before reaching informed consent about this surgical intervention. Additional preventive measures should be considered to reduce this complication rate.
Similar articles
-
SURGICAL REMOVAL OF DENSE POSTERIOR CAPSULE OPACIFICATION AND VITREOUS FLOATERS IN ADULTS BY POSTERIOR CONTINUOUS CURVILINEAR CAPSULORHEXIS THROUGH THE PARS PLANA AND 23-GAUGE VITRECTOMY.Retina. 2016 Nov;36(11):2080-2086. doi: 10.1097/IAE.0000000000001037. Retina. 2016. PMID: 27078801
-
Safety, efficacy, and quality of life following sutureless vitrectomy for symptomatic vitreous floaters.Retina. 2014 Jun;34(6):1055-61. doi: 10.1097/IAE.0000000000000063. Retina. 2014. PMID: 24384616
-
Nd:YAG vitreolysis and pars plana vitrectomy: surgical treatment for vitreous floaters.Eye (Lond). 2002 Jan;16(1):21-6. doi: 10.1038/sj.eye.6700026. Eye (Lond). 2002. PMID: 11913884
-
Vitrectomy for vitreous floaters: analysis of the benefits and risks.Curr Opin Ophthalmol. 2015 May;26(3):173-6. doi: 10.1097/ICU.0000000000000150. Curr Opin Ophthalmol. 2015. PMID: 25784107 Review.
-
Endophthalmitis after pars plana vitrectomy. The Postvitrectomy Endophthalmitis Study Group.Ophthalmology. 1995 May;102(5):705-12. doi: 10.1016/s0161-6420(95)30965-7. Ophthalmology. 1995. PMID: 7777268 Review.
Cited by
-
Efficacy and safety of 'dropless vitrectomy surgery' and comparison of outcomes to standard of care topical therapy.Front Ophthalmol (Lausanne). 2023 Jul 28;3:1215968. doi: 10.3389/fopht.2023.1215968. eCollection 2023. Front Ophthalmol (Lausanne). 2023. PMID: 38983021 Free PMC article.
-
Posterior sub-Tenon triamcinolone injection in the treatment of postoperative cystoid macular edema secondary to pars plana vitrectomy.Indian J Ophthalmol. 2023 Jan;71(1):174-179. doi: 10.4103/ijo.IJO_621_22. Indian J Ophthalmol. 2023. PMID: 36588230 Free PMC article.
-
Dietary Intervention With a Targeted Micronutrient Formulation Reduces the Visual Discomfort Associated With Vitreous Degeneration.Transl Vis Sci Technol. 2021 Oct 4;10(12):19. doi: 10.1167/tvst.10.12.19. Transl Vis Sci Technol. 2021. PMID: 34647961 Free PMC article. Clinical Trial.
-
Impaired Visual Function in Posterior Vitreous Detachment Assessed With the Active-Learning Quantitative Contrast Sensitivity Function Test.J Vitreoretin Dis. 2024 Jul 30;8(5):533-539. doi: 10.1177/24741264241259245. eCollection 2024 Sep-Oct. J Vitreoretin Dis. 2024. PMID: 39351501 Free PMC article.
-
Mid-term safety and effectiveness of intravitreal dexamethasone implant to treat persistent cystoid macular edema in vitrectomized eyes for bacterial endophthalmitis.Graefes Arch Clin Exp Ophthalmol. 2022 Aug;260(8):2703-2710. doi: 10.1007/s00417-022-05615-8. Epub 2022 Mar 7. Graefes Arch Clin Exp Ophthalmol. 2022. PMID: 35254512
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous